Capital International Sarl Raises Stock Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Capital International Sarl increased its Thermo Fisher Scientific stake by 7.4% in the fourth quarter, buying 7,317 more shares and bringing its total holding to 106,535 shares worth about $61.7 million.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $5.44 versus estimates of $5.25 and revenue of $11.01 billion versus expectations of $10.86 billion. Revenue rose 6.2% year over year.
• Insiders and analysts gave mixed signals: COO Gianluca Pettiti sold 400 shares under a pre-arranged trading plan, while Wall Street currently has a “Moderate Buy” consensus and a $613.67 average price target.

Capital International Sarl boosted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 7.4% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 106,535 shares of the medical research company's stock after purchasing an additional 7,317 shares during the period. Thermo Fisher Scientific makes up 1.0% of Capital International Sarl's holdings, making the stock its 26th biggest holding. Capital International Sarl's holdings in Thermo Fisher Scientific were worth $61,732,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of TMO. High Note Wealth LLC raised its stake in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after purchasing an additional 29 shares during the period. JPL Wealth Management LLC purchased a new position in Thermo Fisher Scientific during the third quarter worth about $28,000. Beacon Financial Strategies CORP purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Olistico Wealth LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $29,000. Finally, Core Wealth Advisors LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $30,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Trading Down 1.9%

Shares of TMO stock opened at $472.98 on Friday. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The stock has a market capitalization of $175.77 billion, a P/E ratio of 26.00, a price-to-earnings-growth ratio of 2.09 and a beta of 0.88. The company has a 50 day moving average price of $479.94 and a 200 day moving average price of $531.08. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. The firm had revenue of $11.01 billion during the quarter, compared to analysts' expectations of $10.86 billion. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Investors of record on Monday, June 15th will be issued a $0.47 dividend. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific's payout ratio is 10.34%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on TMO shares. Royal Bank Of Canada set a $490.00 price target on shares of Thermo Fisher Scientific and gave the company a "sector perform" rating in a research report on Thursday, May 14th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Friday, April 24th. Stifel Nicolaus dropped their price target on shares of Thermo Fisher Scientific from $700.00 to $600.00 and set a "buy" rating for the company in a research report on Friday, April 24th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Thermo Fisher Scientific in a research report on Wednesday, April 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $613.67.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.